标题
Immunosuppressive Drugs and COVID-19: A Review
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-08-28
DOI
10.3389/fphar.2020.01333
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- COVID-19 infection: the perspectives on immune responses
- (2020) Yufang Shi et al. CELL DEATH AND DIFFERENTIATION
- Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients
- (2020) Yun Ling et al. CHINESE MEDICAL JOURNAL
- The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
- (2020) Wen Zhang et al. CLINICAL IMMUNOLOGY
- Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
- (2020) Kaijin Xu et al. CLINICAL INFECTIOUS DISEASES
- Early Short Course Corticosteroids in Hospitalized Patients with COVID-19
- (2020) Raef Fadel et al. CLINICAL INFECTIOUS DISEASES
- Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China
- (2020) Jianlei Cao et al. CLINICAL INFECTIOUS DISEASES
- Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China
- (2020) Pingzheng Mo et al. CLINICAL INFECTIOUS DISEASES
- Tocilizumab in transplantation
- (2020) Banafsheh Mosharmovahed et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- (2020) Ruggero Capra et al. European Journal of Internal Medicine
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
- (2020) Corrado Campochiaro et al. European Journal of Internal Medicine
- Risk-adapted Treatment Strategy For COVID-19 Patients
- (2020) Changcheng Zheng et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan
- (2020) Xiaochen Li et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care
- (2020) Luca Quartuccio et al. JOURNAL OF CLINICAL VIROLOGY
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
- (2020) Hasan K. Siddiqi et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19
- (2020) Xiaowei Fang et al. JOURNAL OF INFECTION
- Why tocilizumab could be an effective treatment for severe COVID-19?
- (2020) Binqing Fu et al. Journal of Translational Medicine
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients
- (2020) T. Klopfenstein et al. MEDECINE ET MALADIES INFECTIEUSES
- Corticosteroid treatment of patients with coronavirus disease 2019 ( COVID ‐19)
- (2020) Lei Zha et al. MEDICAL JOURNAL OF AUSTRALIA
- Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal
- (2020) Verónica López et al. NEFROLOGIA
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
- (2020) Chaomin Wu et al. JAMA Internal Medicine
- Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
- (2020) M. Cellina et al. Diagnostic and Interventional Imaging
- Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
- (2020) Yadi Zhou et al. Cell Discovery
- Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
- (2020) Marta Colaneri et al. Microorganisms
- Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
- (2020) Emanuel Della-Torre et al. ANNALS OF THE RHEUMATIC DISEASES
- IMPACT OF GLUCOCORTICOID TREATMENT IN SARS-COV-2 INFECTION MORTALITY: A RETROSPECTIVE CONTROLLED COHORT STUDY
- (2020) Ana Fernández Cruz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19
- (2020) Sijia Li et al. CLINICAL INFECTIOUS DISEASES
- Bloodstream infections in critically ill patients with COVID‐19
- (2020) Daniele Roberto Giacobbe et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Cyclophilin Inhibitors Restrict Middle East Respiratory Syndrome Coronavirus Via Interferon λ In Vitro And In Mice
- (2020) Lucie Sauerhering et al. EUROPEAN RESPIRATORY JOURNAL
- A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome
- (2020) Sajad Khiali et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Methylprednisolone added to tocilizumab reduces mortality in SARS‐CoV‐2 pneumonia: An observational study
- (2020) F. Sanz Herrero et al. JOURNAL OF INTERNAL MEDICINE
- Antiviral activities of mycophenolic acid and IMD‐0354 against SARS‐CoV‐2
- (2020) Fumihiro Kato et al. MICROBIOLOGY AND IMMUNOLOGY
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes in patients with severe COVID-19 disease treated with tocilizumab: a case–controlled study
- (2020) G Rojas-Marte et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia
- (2020) Mingli Yuan et al. SHOCK
- A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial
- (2020) Jonathan Rilinger et al. Trials
- Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19
- (2020) Xudan Chen et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study
- (2019) Sarah H. Alfaraj et al. Travel Medicine and Infectious Disease
- High-throughput Screening and Identification of Potent Broad-spectrum Inhibitors of Coronaviruses
- (2019) Liang Shen et al. JOURNAL OF VIROLOGY
- Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication
- (2019) Yue Ma-Lauer et al. ANTIVIRAL RESEARCH
- Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
- (2018) Yaseen M. Arabi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model
- (2018) H.S. Li et al. ANTIVIRAL RESEARCH
- Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
- (2018) Min-Han Lin et al. ANTIVIRAL RESEARCH
- The role of adjuvant immunomodulatory agents for treatment of severe influenza
- (2018) David S. Hui et al. ANTIVIRAL RESEARCH
- Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists
- (2018) Hiroki Mitoma et al. CYTOKINE
- MERS, SARS and other coronaviruses as causes of pneumonia
- (2017) Yudong Yin et al. RESPIROLOGY
- Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance
- (2016) Chunlong Ma et al. ANTIVIRAL RESEARCH
- Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
- (2016) Mohammed Al Ghamdi et al. BMC INFECTIOUS DISEASES
- SARS and MERS: recent insights into emerging coronaviruses
- (2016) Emmie de Wit et al. NATURE REVIEWS MICROBIOLOGY
- Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
- (2015) Kai-Wen Cheng et al. ANTIVIRAL RESEARCH
- Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
- (2015) Jasper Fuk-Woo Chan et al. JOURNAL OF INFECTIOUS DISEASES
- Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
- (2015) Reed F. Johnson et al. VIROLOGY
- Antiviral Potential of ERK/MAPK and PI3K/AKT/mTOR Signaling Modulation for Middle East Respiratory Syndrome Coronavirus Infection as Identified by Temporal Kinome Analysis
- (2014) Jason Kindrachuk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
- (2014) Javier Carbajo-Lozoya et al. VIRUS RESEARCH
- Interferon- and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
- (2013) B. J. Hart et al. JOURNAL OF GENERAL VIROLOGY
- MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- treatment
- (2013) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
- (2013) Jasper F.W. Chan et al. JOURNAL OF INFECTION
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
- (2013) V. Stalin Raj et al. NATURE
- Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
- (2012) Javier Carbajo-Lozoya et al. VIRUS RESEARCH
- Cyclosporin A inhibits the replication of diverse coronaviruses
- (2011) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- The SARS-Coronavirus-Host Interactome: Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors
- (2011) Susanne Pfefferle et al. PLoS Pathogens
- The SARS outbreak in a general hospital in Tianjin, China: clinical aspects and risk factors for disease outcome
- (2009) Mao-Ti Wei et al. TROPICAL MEDICINE & INTERNATIONAL HEALTH
- Mouse-Passaged Severe Acute Respiratory Syndrome-Associated Coronavirus Leads to Lethal Pulmonary Edema and Diffuse Alveolar Damage in Adult but Not Young Mice
- (2008) Noriyo Nagata et al. AMERICAN JOURNAL OF PATHOLOGY
- Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus
- (2008) Chi-Yuan Chou et al. BIOCHEMICAL PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started